
Long-acting Contraception Market by Type (Long-Acting Contraceptives, Short-Acting Contraceptives), Product (Injectables, Intrauterine Devices, Subdermal Implants), Application, End-use - Global Forecast 2024-2030
Description
Long-acting Contraception Market by Type (Long-Acting Contraceptives, Short-Acting Contraceptives), Product (Injectables, Intrauterine Devices, Subdermal Implants), Application, End-use - Global Forecast 2024-2030
The Long-acting Contraception Market size was estimated at USD 3.42 billion in 2023 and expected to reach USD 3.68 billion in 2024, at a CAGR 7.06% to reach USD 5.52 billion by 2030.
Global Long-acting Contraception Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Long-acting Contraception Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Long-acting Contraception Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Long-acting Contraception Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayer AG, DKT International, HRA Pharma SAS by Perrigo Company plc, Merck & Co., Inc., Meril Life Sciences Pvt. Ltd., Mona Lisa N.V., OCON Healthcare, Pfizer Inc., Pregna International Limited, Prosan International B.V., SMB Corporation of India, Teva Pharmaceuticals Industries Ltd., The Cooper Companies, Inc., and Viatris Inc..
Market Segmentation & Coverage
This research report categorizes the Long-acting Contraception Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Long-Acting Contraceptives
Short-Acting Contraceptives
Product
Injectables
Intrauterine Devices
Subdermal Implants
Application
Contraception
HIV
Schizophrenia
End-use
Drug Store
E-Commerce
Hospital
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Long-acting Contraception Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Long-acting Contraception Market?
3. What are the technology trends and regulatory frameworks in the Long-acting Contraception Market?
4. What is the market share of the leading vendors in the Long-acting Contraception Market?
5. Which modes and strategic moves are suitable for entering the Long-acting Contraception Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Long-acting Contraception Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising adoption of long term contraception among male and female
- 5.1.1.2. Rising publicly funded family planning services
- 5.1.2. Restraints
- 5.1.2.1. Associated side effects of long term contraception
- 5.1.3. Opportunities
- 5.1.3.1. Introduction of technically advanced long term contraception methods
- 5.1.3.2. Strong government support for LTC
- 5.1.4. Challenges
- 5.1.4.1. Concern regarding limited approved products
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Long-acting Contraception Market, by Type
- 6.1. Introduction
- 6.2. Long-Acting Contraceptives
- 6.3. Short-Acting Contraceptives
- 7. Long-acting Contraception Market, by Product
- 7.1. Introduction
- 7.2. Injectables
- 7.3. Intrauterine Devices
- 7.4. Subdermal Implants
- 8. Long-acting Contraception Market, by Application
- 8.1. Introduction
- 8.2. Contraception
- 8.3. HIV
- 8.4. Schizophrenia
- 9. Long-acting Contraception Market, by End-use
- 9.1. Introduction
- 9.2. Drug Store
- 9.3. E-Commerce
- 9.4. Hospital
- 10. Americas Long-acting Contraception Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Long-acting Contraception Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.
- 10. South Korea
- 11.
- 11. Taiwan
- 11.
- 12. Thailand
- 11.
- 13. Vietnam
- 12. Europe, Middle East & Africa Long-acting Contraception Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.
- 10. Nigeria
- 12.
- 11. Norway
- 12.
- 12. Poland
- 12.
- 13. Qatar
- 12.
- 14. Russia
- 12.
- 15. Saudi Arabia
- 12.
- 16. South Africa
- 12.
- 17. Spain
- 12.
- 18. Sweden
- 12.
- 19. Switzerland
- 12.
- 20. Turkey
- 12.
- 21. United Arab Emirates
- 12.
- 22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. AbbVie Inc.
- 14.1.2. Bayer AG
- 14.1.3. DKT International
- 14.1.4. HRA Pharma SAS by Perrigo Company plc
- 14.1.5. Merck & Co., Inc.
- 14.1.6. Meril Life Sciences Pvt. Ltd.
- 14.1.7. Mona Lisa N.V.
- 14.1.8. OCON Healthcare
- 14.1.9. Pfizer Inc.
- 14.1.
- 10. Pregna International Limited
- 14.1.
- 11. Prosan International B.V.
- 14.1.
- 12. SMB Corporation of India
- 14.1.
- 13. Teva Pharmaceuticals Industries Ltd.
- 14.1.
- 14. The Cooper Companies, Inc.
- 14.1.
- 15. Viatris Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. LONG-ACTING CONTRACEPTION MARKET RESEARCH PROCESS
- FIGURE 2. LONG-ACTING CONTRACEPTION MARKET SIZE, 2023 VS 2030
- FIGURE 3. LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. LONG-ACTING CONTRACEPTION MARKET DYNAMICS
- FIGURE 7. LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
- FIGURE 10. LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 12. LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
- FIGURE 14. LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.